ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Fluorination as a Molecular Design Parameter for Programming Peptide Nanocarriers.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Peptide-based nanocarriers offer unique opportunities for programmable self-assembly (SA), yet rational design strategies that couple structural control with biological function remain limited. In particular, fluoropeptides have been largely inaccessible as modular building blocks until the recent availability of enantiomerically pure fluorinated amino acids (FAAs) in gram-scale quantities, preventing their systematic use in functional nanomaterials. Here, we introduce fluorination as a quantitative molecular design parameter to program peptide SA, morphology, and biological performance. A homologous series of amphiphilic fluoropeptide-RGD conjugates was constructed in which the degree of side-chain fluorination is precisely controlled. We show that fluorination does not monotonically enhance assembly, but instead defines a narrow design window in which compact, non-amyloid fibrillar architectures emerge. Mechanistic insight from molecular dynamics (MD) simulations reveals how fluorine-induced modulation of hydrophobic interactions and hydration disrupts classical β-sheet packing. The optimized trifluorinated conjugate exhibits high drug-loading capacity, pH-triggered release, receptor-specific cellular uptake, and low cytotoxicity, while remaining enzymatically degradable. Together, these results establish fluorinated peptide segments as a previously inaccessible and programmable handle for the rational design of peptide-based nanocarriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.